Revvity price target raised to $125 from $115 at Jefferies

Jefferies analyst Tycho Peterson raised the firm’s price target on Revvity to $125 from $115 and keeps a Hold rating on the shares. The firm says Q2 saw solid revenues and EPS upside, with full year EPS going higher. Headwinds remain, but the tone was cautiously optimistic on biopharma, China prenatal screening and applied genomics, Jefferies notes. The firm also points out that while capital deployment preference is share repos, magnitude is less than peers despite improved free cash flow.